Cargando…
COVID‐19 and COVID‐19 vaccine‐related dermatological reactions: An interesting case series with a narrative review of the potential critical and non‐critical mucocutaneous adverse effects related to virus, therapy, and the vaccination
This narrative review article was conducted to lay out a summarized but exhaustive review of current literature over mucocutaneous manifestations in 4 dimensions of SARS‐CoV‐2 pandemic: virus itself, treatment‐related, vaccine‐induced, and alteration of chronic dermatologic diseases following infect...
Autores principales: | Pour Mohammad, Arash, Mashayekhi, Farzaneh, Seirafianpour, Farnoosh, Gholizadeh Mesgarha, Milad, Goodarzi, Azadeh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040420/ https://www.ncbi.nlm.nih.gov/pubmed/35498347 http://dx.doi.org/10.1002/ccr3.5775 |
Ejemplares similares
-
Predictors of critical COVID-19 in an Iranian population: Age and disabilities play a special role
por: Bidari, Ali, et al.
Publicado: (2021) -
Constrictive pericarditis following inactivated virus COVID-19 vaccine: a case report with review of the literature()
por: Hajsadeghi, Shokoufeh, et al.
Publicado: (2022) -
Mucocutaneous presentations of consultant critical and non-critical cases of admitted COVID-19 patients, outpatients, and vaccine-associated dermatoses: a clinical atlas and a large original study of two general COVID-19 centers from Iran
por: Sadeghzadeh-Bazargan, Afsaneh, et al.
Publicado: (2023) -
Simultaneous Occurrence of Cerebral Venous Sinus Thrombosis and Immune Thrombocytopenic Purpura in a Patient with a History of COVID-19 Infection
por: Bahadorizadeh, Leyla, et al.
Publicado: (2021) -
A systematic review and meta‐analysis of investigating the mutual impact of COVID‐19 and psoriasis: Focusing on COVID‐19 course in psoriasis and the opinion on biologics in this setting
por: Ghoreishi Amin, Nazila, et al.
Publicado: (2023)